Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEPW) Payables (2021 - 2025)

Coeptis Therapeutics Holdings has reported Payables over the past 5 years, most recently at $988755.0 for Q4 2025.

  • Quarterly results put Payables at $988755.0 for Q4 2025, down 27.82% from a year ago — trailing twelve months through Dec 2025 was $988755.0 (down 27.82% YoY), and the annual figure for FY2025 was $988755.0, down 27.82%.
  • Payables for Q4 2025 was $988755.0 at Coeptis Therapeutics Holdings, up from $783103.0 in the prior quarter.
  • Over the last five years, Payables for COEPW hit a ceiling of $3.6 million in Q1 2024 and a floor of $31816.0 in Q1 2021.
  • Median Payables over the past 5 years was $1.5 million (2022), compared with a mean of $1.5 million.
  • Biggest five-year swings in Payables: soared 3236.15% in 2022 and later plummeted 70.87% in 2025.
  • Coeptis Therapeutics Holdings' Payables stood at $2.6 million in 2021, then fell by 23.6% to $1.9 million in 2022, then grew by 17.74% to $2.3 million in 2023, then plummeted by 40.31% to $1.4 million in 2024, then decreased by 27.82% to $988755.0 in 2025.
  • The last three reported values for Payables were $988755.0 (Q4 2025), $783103.0 (Q3 2025), and $1.1 million (Q2 2025) per Business Quant data.